Exchange Traded Concepts LLC Has $180,000 Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Exchange Traded Concepts LLC decreased its position in Compass Therapeutics, Inc. (NASDAQ:CMPXFree Report) by 12.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 97,931 shares of the company’s stock after selling 14,089 shares during the period. Exchange Traded Concepts LLC owned approximately 0.07% of Compass Therapeutics worth $180,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Opaleye Management Inc. bought a new stake in Compass Therapeutics during the 1st quarter worth approximately $6,277,000. CM Management LLC raised its holdings in shares of Compass Therapeutics by 148.0% during the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock worth $614,000 after acquiring an additional 185,000 shares during the period. Ground Swell Capital LLC bought a new stake in Compass Therapeutics in the 2nd quarter valued at $124,000. Vanguard Group Inc. lifted its position in Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after acquiring an additional 71,008 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after purchasing an additional 70,200 shares during the period. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Trading Down 0.5 %

NASDAQ CMPX opened at $1.85 on Tuesday. The firm has a market capitalization of $254.54 million, a P/E ratio of -5.14 and a beta of 0.90. The firm’s fifty day moving average price is $1.60 and its two-hundred day moving average price is $1.39. Compass Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $2.34.

Compass Therapeutics (NASDAQ:CMPXGet Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). The business had revenue of $0.85 million for the quarter. On average, research analysts anticipate that Compass Therapeutics, Inc. will post -0.42 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Monday, August 12th. Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Monday, September 16th.

Read Our Latest Report on Compass Therapeutics

Compass Therapeutics Company Profile

(Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Read More

Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPXFree Report).

Institutional Ownership by Quarter for Compass Therapeutics (NASDAQ:CMPX)

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.